Answers are grounded in this paper and cite their sources.
In 1977, researchers made the groundbreaking discovery that cancer patients carried cell-free DNA in their peripheral blood and introduced interest in this concept as a potential tool for evaluation of cancer prognosis or therapy response. With the advancement in knowledge provided by The Cancer Genome Atlas program and next generation sequencing technology, liquid biopsy via the analysis of non-solid biological tissue has become a promising method of understanding tumor dynamics during treatment . Circulating tumor DNA has gained interest due to the ability to identify tumor-specific somatic genomic mutations while also serving as an effective indicator of minimal residual disease in multiple cancer types.
No takes yet. Share an insight, caveat, or question.
Au et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: